Exploring the role of routine brain imaging in detecting asymptomatic brain metastases in first diagnosed HER2-positive breast cancer
PLOS One · 2025
DOI: 10.1371/journal.pone.0334610 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Carmen Leser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Brain. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
HER2-positive breast cancer is leading to aggressive tumor growth and a higher risk of metastasis, particularly to the central nervous system (CNS). Routine brain imaging for asymptomatic HER2-positive patients is debated, with no current consensus; Given the severe clinical implications of brain metastases, further research is needed to determine the cost-effectiveness and clinical utility of routine imaging for high-risk patients to improve outcomes and inform targeted screening protocols.
Methods
This retrospective, monocentric study at the General Hospital of Vienna (AKH Wien) examined female HER2-positive breast cancer patients at first diagnosis to assess brain metastasis from January 2019 to February 2024. The study included patients with asymptomatic confirmed HER2 positive breast cancer. Data were collected through comprehensive medical records and brain imaging with MRI.
Results
Among 110 female patients meeting the inclusion criteria, 4 (3.6%) were diagnosed with brain metastases. Ki67 showed a marginal association with brain metastasis (p = 0.054), and tumor grade was a significant predictor, with intermediate differentiated tumors (G2 vs. G3) associated with a higher risk of brain metastases (p = 0.041) and brain metases are correlating with the axillary lymphnode status and the tumor sizeAlso, the absence of positive Östrogen and Progesteron receptors is a predictor in upcoming brain metastases (p < 0.001). Other factors like age were not significantly associated.
Conclusion
This study found limited benefit in routine MRI for detecting asymptomatic brain metastases in HER2-positive breast cancer, given the low prevalence (3.6%). A targeted imaging approach for high-risk patients, like those with the absence of Hormon receptors and higher stage tumors, may be effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
- Institute for Artificial Intelligence, Medical University of Vienna, Vienna, Austria.
- Research Centre for Medical Imaging and Image Analysis (MIAAI), Danube Private University, Krems, Austria.
- Institute for Musculoskeletal imaging, Karl Landsteiner Society, St. Pölten, Austria.
ORCID-Profile: Carmen Leser
Zitieren
APA
Leser, C., Kabashi, F., Dorffner, G., Zaric, O., Deutschmann, C., & Gschwantler-Kaulich, D. (2025). Exploring the role of routine brain imaging in detecting asymptomatic brain metastases in first diagnosed HER2-positive breast cancer. PLOS One. https://doi.org/10.1371/journal.pone.0334610
Vancouver
Leser C, Kabashi F, Dorffner G, Zaric O, Deutschmann C, Gschwantler-Kaulich D. Exploring the role of routine brain imaging in detecting asymptomatic brain metastases in first diagnosed HER2-positive breast cancer. PLOS One. 2025. doi:10.1371/journal.pone.0334610
BibTeX
@article{Leser2025,
author = {Leser, Carmen and Kabashi, Fiona and Dorffner, Georg and Zaric, Olgica and Deutschmann, Christine and Gschwantler-Kaulich, Daphne},
title = {Exploring the role of routine brain imaging in detecting asymptomatic brain metastases in first diagnosed HER2-positive breast cancer},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334610}
}
EUVIMED